Your session is about to expire
← Back to Search
NEO-201 + Pembrolizumab for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new cancer drug, NEO-201, to see if it is safe and effective. So far, the results look promising, with the Maximum Tolerated Dose being 1.5mg/kg. The Expansion Phase of the study is now enrolling patients with non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical and uterine cancers.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: NEO-201 in combination with pembrolizumab
Frequently Asked Questions
What prior experiments have been conducted with the combination of NEO-201 and pembrolizumab?
"The current tally of active studies for NEO-201 in combination with pembrolizumab stands at 961, with 122 trials in the latter stages. Houston, Texas is home to the largest share of these clinical trials; however, there are 35731 sites conducting related research across all regions."
Is there any availability for subjects to join this trial?
"Searching for participants, this clinical trial was initially posted on January 18th 2019 and last updated April 1st 2022 per the information provided by clinicaltrials.gov."
In what cases is the pairing of NEO-201 and pembrolizumab generally prescribed?
"NEO-201 and pembrolizumab are usually prescribed as a combination therapy to treat malignant neoplasms, however they can also be effective at managing unresectable melanoma, microsatellite instability high diseases that have progressed after chemotherapy."
How many volunteers are presently participating in this investigation?
"Affirmative. According to information hosted on clinicaltrials.gov, this experimental trial which was initially posted in January 18th 2019 is actively searching for participants. The study requires 121 individuals at a single location."
What end-goals is this experiment attempting to reach?
"This clinical trial has a primary objective of evaluating the safety of NEO-201 in combination with pembrolizumab via revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 over 1.5 years. Secondary objectives include measuring area under concentration-time curve (AUC), minimum plasma concentration (Cmin), and peak plasma concentration (Cmax). Samples will be collected at various intervals to monitor drug exposure, trough concentrations, and peak concentrations respectively."
Share this study with friends
Copy Link
Messenger